Aaron Rosenberg
Chief Financial OfficerMr. Aaron Rosenberg is Chief Financial Officer of BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) from July 22, 2024. Mr. Rosenberg joined BeOne in July 2024. Mr. Rosenberg is a global finance executive with more than two decades of experience at Merck & Co., Inc, known as Merck Sharp & Dohme outside of the United States and Canada. He was most recently Senior Vice President and Corporate Treasurer of Merck from 2021. Prior to his role as Corporate Treasurer, Mr. Rosenberg served as Senior Vice President of Corporate Strategy and Planning at Merck from 2018 to 2021 with responsibilities including leading the enterprise-wide business transformation team and acting as Head of Financial Planning & Analysis. Mr. Rosenberg was Vice President and Finance Lead of Merck Animal Health from 2015 to 2018, leading a global team of 120 colleagues. He joined Merck in 2003 in ascending leadership roles in the global finance organization. Mr. Rosenberg received a Bachelor of Science in Finance from the Warrington College of Business at the University of Florida and a Master of Business Administration from the Leonard N. Stern School of Business at New York University.
Positions
- Company NameBeOne Medicines AGStock Code06160PositionChief Financial OfficerRelated SecuritiesColleagues
- JVJohn V. OylerCo-Founder, Executive Chairman & CEO
- WLWang LaiPresident and Global Head of Research & Development
- XWXiaodong WangCo-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder
- CLChan LeeGeneral Counsel, Senior VP & Corporate Secretary
- ACAnthony C. HooperChairman of Commercial & Medical Affairs Advisory Committee and Ind. Non Executive Director
- MHMargaret Han DuganMember of Scientific Advisory Committee & Independent Non-Exec. Director
- SSShalini SharpIndependent Non-Executive Director
